Dogwood Therapeutics, INC. (DWTX) — 8-K Filings

8-K Filings (25)

• Dogwood Therapeutics Files 8-K: Regulation FD Disclosure — Mar 26, 2026
  Dogwood Therapeutics, Inc. filed an 8-K on March 26, 2026, under Item 7.01, Regulation FD Disclosure, indicating they are making a public announcement of materi
• 8-K Filing — Nov 28, 2025
• 8-K Filing — Nov 21, 2025
• 8-K Filing — Nov 6, 2025
• Dogwood Therapeutics Files 8-K on Key Corporate Events — Sep 29, 2025 Risk: medium
  On September 29, 2025, Dogwood Therapeutics, Inc. filed an 8-K report detailing several material events. These include entering into a material definitive agree
• Dogwood Therapeutics Announces Director and Officer Changes — Jul 2, 2025 Risk: medium
  Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed an 8-K on July 2, 2025, reporting changes effective June 27, 2025. The filing details the
• Dogwood Therapeutics Files 8-K: Board & Compensation Updates — Jun 24, 2025 Risk: medium
  Dogwood Therapeutics, Inc. announced on June 18, 2025, a change in its board of directors and executive compensation arrangements. The company also filed financ
• Dogwood Therapeutics Files 8-K on Financials — May 8, 2025 Risk: low
  Dogwood Therapeutics, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing also includes financial state
• Dogwood Therapeutics Files 8-K with Exhibits — Apr 3, 2025 Risk: low
  On April 3, 2025, Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed an 8-K report. The filing primarily concerns financial statements and ex
• Dogwood Therapeutics Enters Material Definitive Agreement — Mar 14, 2025 Risk: medium
  On March 12, 2025, Dogwood Therapeutics, Inc. entered into a material definitive agreement. The company, formerly known as Virios Therapeutics, Inc., is a pharm
• Dogwood Therapeutics Files 8-K with Key Corporate Updates — Mar 12, 2025 Risk: medium
  On March 12, 2025, Dogwood Therapeutics, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreem
• Dogwood Therapeutics Faces Delisting Concerns — Nov 21, 2024 Risk: high
  Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed an 8-K on November 21, 2024, reporting a notice of delisting or failure to satisfy a conti
• Dogwood Therapeutics Files 8-K on Financials — Nov 7, 2024 Risk: low
  Dogwood Therapeutics, Inc. (formerly Virios Therapeutics, Inc.) filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition
• Dogwood Therapeutics Files 8-K — Oct 30, 2024 Risk: low
  Dogwood Therapeutics, Inc. filed an 8-K on October 30, 2024, reporting on events and financial statements as of October 29, 2024. The company, formerly known as
• Virios Therapeutics Acquires 03 Life Sciences — Oct 7, 2024 Risk: medium
  Virios Therapeutics, Inc. announced on October 4, 2024, the completion of its acquisition of 03 Life Sciences, a company focused on developing novel treatments
• Virios Therapeutics Files 8-K — Aug 8, 2024 Risk: low
  Virios Therapeutics, Inc. filed an 8-K on August 8, 2024, to report on its results of operations and financial condition, and to file financial statements and e
• Virios Therapeutics Reports on Shareholder Vote — Jun 20, 2024 Risk: low
  Virios Therapeutics, Inc. filed an 8-K on June 20, 2024, reporting on a matter submitted to a vote of security holders on June 18, 2024. The filing details the
• Virios Therapeutics Faces Delisting Notice — Jun 12, 2024 Risk: high
  Virios Therapeutics, Inc. filed an 8-K on June 12, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is based in
• Virios Therapeutics Enters Material Definitive Agreement — May 20, 2024 Risk: medium
  Virios Therapeutics, Inc. announced on May 19, 2024, that it entered into a Material Definitive Agreement. The company, incorporated in Delaware with its princi
• Virios Therapeutics Files 8-K on Financials — May 9, 2024 Risk: low
  Virios Therapeutics, Inc. filed an 8-K on May 9, 2024, to report on its results of operations and financial condition. The filing also includes financial statem
• Virios Therapeutics Faces Delisting Concerns — May 7, 2024 Risk: high
  Virios Therapeutics, Inc. filed an 8-K on May 7, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, incorporated
• Virios Therapeutics Files 8-K on Security Holder Vote — Mar 6, 2024 Risk: low
  Virios Therapeutics, Inc. filed an 8-K on March 6, 2024, reporting on a matter submitted to a vote of security holders as of March 1, 2024. The filing does not
• Virios Therapeutics Files 8-K on Financials — Feb 29, 2024 Risk: low
  Virios Therapeutics, Inc. filed an 8-K on February 29, 2024, reporting on its results of operations and financial condition. The filing details the company's st
• Virios Therapeutics Reports Officer/Director Changes, Compensation — Feb 27, 2024 Risk: medium
  Virios Therapeutics, Inc. filed an 8-K on February 27, 2024, reporting events that occurred on February 26, 2024. The filing indicates changes related to the de
• Virios Therapeutics Files Administrative 8-K; No New Material Events — Jan 3, 2024
  Virios Therapeutics, Inc. filed an 8-K on January 3, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded compa

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX